Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Mehmet Asim Bilen"'
Publikováno v:
Frontiers in Oncology. 13
Autor:
Tony Zibo Zhuang, Lara Harik, Seth Force, Agreen Hadadi, Mehmet Asim Bilen, Jacqueline T. Brown, Bradley C. Carthon, Jamie Goldman, Omer Kucuk, Viraj A. Master, Bassel Nazha
Publikováno v:
Frontiers in Oncology. 12
The role of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma is a subject of debate. We report a durable complete response in a 62-year-old man Jehovah’s Witness with metastatic clear cell renal cell carcinoma who received
Autor:
Dylan J. Martini, Caroline S. Jansen, Lara R. Harik, Sean T. Evans, T. Anders Olsen, Viraj A. Master, Haydn T. Kissick, Mehmet Asim Bilen
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
Translocation-associated renal cell carcinoma (tRCC) is a rare, aggressive malignancy that primarily affects children and young adults. There is no clear consensus on the most effective treatment for tRCC and there are no biomarkers of response to tr
Autor:
Dylan J. Martini, T. Anders Olsen, Subir Goyal, Yuan Liu, Sean T. Evans, Benjamin Magod, Jacqueline T. Brown, Lauren Yantorni, Greta Anne Russler, Sarah Caulfield, Jamie M. Goldman, Bassel Nazha, Haydn T. Kissick, Wayne B. Harris, Omer Kucuk, Bradley C. Carthon, Viraj A. Master, Mehmet Asim Bilen
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology
Frontiers in Oncology
BackgroundImmune checkpoint inhibitors (ICI) have revolutionized the treatment of metastatic renal cell carcinoma (mRCC). Biomarkers for mRCC patients treated with ICI are limited, and body composition is underutilized in mRCC. We investigated the as
Autor:
T. Anders Olsen, Dylan J. Martini, Subir Goyal, Yuan Liu, Sean T. Evans, Benjamin Magod, Jacqueline T. Brown, Lauren Yantorni, Greta Anne Russler, Sarah Caulfield, Jamie M. Goldman, Wayne B. Harris, Omer Kucuk, Bradley C. Carthon, Viraj A. Master, Bassel Nazha, Mehmet Asim Bilen
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
BackgroundImmune-checkpoint-inhibitors (ICIs) have become the cornerstone of metastatic renal-cell-carcinoma (mRCC) therapy. However, data are limited regarding clinical outcomes by race. In this study, we compared the real-world outcomes between Afr
Autor:
Mehmet Asim Bilen, Jodi Lyn Layton, Whitley Hatton, Hamid Emamekhoo, Vadim S. Koshkin, Patrick Cotogno, Arpita Desai, Ellen Jaeger, Oliver Sartor, Charlotte Manogue, Pedro C. Barata, Brian E. Lewis, Arnab Basu, Deepak Kilari, Malcolm Light
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology
Frontiers in Oncology
Introduction: The treatment landscape of metastatic renal cell carcinoma has advanced significantly with the approval of combination regimens containing an immune checkpoint inhibitor (ICI) for patients with treatment-naive disease. Little informatio